The global pandemic caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐
CoV‐2), named coronavirus disease 2019, has infected more than 8.9 million people …

Major changes have emerged during the last few years in the therapy of patients with
chronic hepatitis C (CHC). Several direct acting antiviral agents (DAAs) have been …

COVID-19 is a devastating global pandemic around the world. While the majority of infected
cases appear mild, in some cases individuals present respiratory complications with …

Abstract Utilization of CuO nanoparticles (NPs) in agriculture, as fertilizers or pesticides,
requires understanding of their impact on plant metabolism. Inhibition of root elongation by …

Background Over the past several years, hepatitis C therapy has been pegylated interferon
and ribavirin based. Although protease inhibitor‐based therapy has enhanced response …

Antiviral drugs such as Remdesivir (Veklury), Nirmatrelvir with Ritonavir (Paxlovid),
Azvudine, and Molnupiravir (Lagevrio) can reduce the risk for severe and fatal Coronavirus …

Nucleotide compounds like sofosbuvir, acyclovir, and tenofovir have proven to be amongst
the most potent orally available antiviral treatments. These drugs exhibit high efficacy and a …

Conclusions: In conclusion, viral population dynamics played a critical role during antiviral
treatment. High population diversity during sofosbuvir treatment led to the selection of …

It is estimated that 58 million people suffer from chronic hepatitis C virus (HCV) infection
worldwide, which significantly contributes to chronic liver disease and liverrelated mortality …

Introduction: Hepatitis C virus (HCV) infection is a worldwide health problem, whose
management has been revolutionized after the availability of sofosbuvir, a direct-acting …